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Background: Dominant-negative somatic mutations of p53 has been identified in the synovium of patients with
rheumatoid arthritis (RA), in which interleukin (IL)-6 has been established as a pivotal inflammatory cytokine. The
aim of this study was to clarify the significance of p53 in the longstanding inflammation in RA by modulating IL-6.
Methods: We established adjuvant-induced arthritis (AIA) in Lewis rats and treated them with p53 activator, and
then analyzed the histopathology of the synovium and IL-6 expression. Human fibroblast-like synoviocytes (FLS)
were cultured and transfected with p53-siRNA or transduced with adenovirus (Ad)-p53, and then assessed with
MTT, TUNEL staining, and luciferase assay. IL-1β, tumor necrosis factor (TNF)-α and IL-17 were used to stimulate FLS,
and subsequent IL-6 expression as well as relevant signal pathways were explored.
Results: p53 significantly reduced synovitis as well as the IL-6 level in the AIA rats. It controlled cell cycle arrest and
proliferation, but not apoptosis. Proinflammatory cytokines inhibited p53 expression in FLS, while p53 significantly
suppressed the production of IL-6. Furthermore, IL-6 expression in p53-deficient FLS was profoundly reduced by
NF-kappaB, p38, JNK, and ERK inhibitors.
Conclusion: Our findings reveal a novel function of p53 in controlling inflammatory responses and suggest that
p53 abnormalities in RA could sustain and accelerate synovial inflammation mainly through IL-6. p53 may be a key
modulator of IL-6 in the synovium and plays a pivotal role in suppressing inflammation by interaction with the
signal pathways in RA-FLS. Interfering with the p53 pathway could therefore be an effective strategy to treat RA.
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Rheumatoid arthritis (RA) is a chronic progressive polyar-
thritis that is characterized by synovial inflammation and
pannus formation, which leads to destruction of cartilage
and bone resulting in joint deformities and disability [1].
The normal synovium consists of an intimal lining with
one to two cell layers, which expand in RA in part due to
increased numbers of fibroblast-like synoviocytes (FLS).* Correspondence: youxinpumch@hotmail.com
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and matrix degrading enzymes that are responsible for
joint inflammation and destruction [2]. The aggressive
properties of RA-FLS are similar to neoplasms, with the
underlying mechanisms that include mutations of tumor
suppressor genes such as p53 [3–6].
A dominant negative mutation of p53 in RA synovium
and FLS has been associated with its dysfunction and
interleukin (IL)-6 production [7]. For many years, this
has been traditionally attributed to insufficient synovio-
cyte apoptosis in RA. While the exact cause of this is
not entirely known, the presence of microsatellite
instability manifested by damaged DNA and decreasedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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toid synovium could lead to the point mutation of p53
[8]. Animal experiments showed increased disease sever-
ity in p53–/– mice compared to p53+/+ mice in the
collagen-induced arthritis (CIA) model, confirming the
significance of p53 in inflammatory arthritis [9]. How-
ever, adenovirus (Ad)-mediated p53 is not capable of
inducing apoptosis in RA-FLS in vitro. Therefore, we
suspect that this remarkable gene may be involved in
more than just apoptosis, and may instead play distinct-
ive roles in inflammatory arthritis.
Our preliminary research revealed that the p53 activa-
tor (Nutlin) ameliorated adjuvant-induced arthritis
(AIA) in Lewis rats, although the effect of p53 did not
appear to be mediated by inducing apoptosis in FLS, and
p53-overexpressed FLS arrested at phase G1. Histologic
analysis of the synovium demonstrated dramatic decreases
in infiltration of inflammatory cells after induction of p53
in vivo. These results raised further questions about the
role of p53 in synovitis since p53-mediated cell cycle ar-
rest might not account for its effect. We now address a
novel, crucial role of p53 in the regulation of synovium
inflammation.Methods
Induction of adjuvant-induced arthritis in rats
Lewis rats were purchased from the animal center in
Peking Union Medical College (PUMC) and were main-
tained under specific pathogen-free conditions at the
PUMC Hospital. All animal procedures were performed
with the approval of the Institutional Animal Care and
Use Committee of the PUMC Hospital.
Lewis rats, 8-week-old females, were given intracutane-
ous (i.c.) injections of Mycobacterium tuberculosis (0.1 mg
emulsified in 100 μl of paraffin oil; Chondrex Inc., Japan)
at the right footpad of the rear paw as described previ-
ously [10]. On day 0 they were randomly divided into
three groups: a Nutlin-treatment group as well as two
control groups designed to receive dimethyl sulfoxide
(DMSO) or phosphate-buffered saline (PBS) (n = 6 for
each). From day 8 to day 12 after induction, rats were ad-
ministered with Nutlin-3 (250 mg/kg in DMSO per day,
intraperitoneally), DMSO, or PBS.
The severity of arthritis was assessed by scoring
arthritis every 3 days and measuring the volume of hind
paw swelling with water displacement on day 8 and day
21 after immunization. The rats then were sacrificed and
the serum and ankle joint homogenates were prepared
for IL-6 detection. Tissues harvested from dissected
ankles were fixed in 10% buffered formalin and decalci-
fied, embedded, sectioned, and stained with hematoxylin
and eosin (H&E) to grade inflammatory and bone
destructive changes. Sections were randomly analyzed.All areas of each section were independently examined
by microscopy by two observers.Human fibroblast-like synoviocyte culture
Synovial tissues were obtained from patients with RA
and osteoarthritis following joint replacement surgery.
The diagnosis of RA met the American College of
Rheumatology 1987 revised criteria [11]. The protocol
was approved by the PUMC Hospital Human Subjects
Research Protection Program. FLS were isolated from
individual tissues with 1 mg/ml collagenase and cultured
in DMEM supplemented with 10% fetal calf serum,
penicillin, streptomycin, and L-glutamine. Cell lines were
used from the third to ninth passage on the basis of
vascular cell adhesion molecule (VCAM)-1 and CD55
expression, when they were a homogeneous population
of fibroblast-like cells [12].Antibodies
Affinity-purified mouse monoclonal anti-p53 for Western
blotting and rabbit polyclonal antibodies against p21 were
purchased from Santa Cruz Biotechnology (Santa Cruz,
USA). Anti-(phospho-) p38, anti-(phospho-) JNK, anti-
(phospho-) ERK, anti-(phospho-) IκBα and anti-mouse
and anti-rabbit IgG secondary antibodies were purchased
from Cell Signaling Technology, Inc. (Beverly, MA, USA).Cell transfections
Scrambled RNA and p53 siRNA were purchased from
Dharmacon Research, Inc. (Lafayette, CO, USA). Cells
were transfected with the use of the Amaxa Human Der-
mal Fibroblast Nucleofactor kit (Amaxa Biosystem,
Germany) with program U-23 for human FLS. Cells (2 ×
105 to 106) were transfected with siRNAs in each reaction.Transduction of adenovirus-p53
To deliver p53 into FLS, recombinant human Ad-p53
was added to serum-free supernatant; multiplicity of in-
fection (MOI) was 100. The plate was shaken every
10 min to ensure full contact of adenovirus with FLS.
The supernatant was then replaced with serum-
supplemented DMEM 3 h later.MTT assay
To measure cell viability, FLS were trypsinized and
washed, and approximately 1 × 104 cells were seeded into
each well of 96-well culture plates. The MTT working
solution was 0.5 mg/ml MTT in PBS for 4 h at 37 °C, then
replaced with DMSO. The plate was analyzed on a spec-
trophotometric plate reader at a test wavelength of
570 nm and a reference wavelength of 630 nm.
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To detect fragmented DNA in FLS and synovium, a
TUNEL kit, DNA nick end labeling (R&D Company,
USA), was used as directed. Nuclei positive for TUNEL
staining were stained with green fluorescence by the
reaction. The level of positive staining was determined
by visual observation through fluorescence microscopy.
Luciferase assay
Cells were transfected with 5 μg of a Bax-promoter-
luciferase construct (bax-luc), or empty vector (pCI) at
day 3 post-siRNA transfection, and harvested 24 h and
60 h after plasmid transfection. Results were normalized
to co-transfected β-galactosidase expression as relative
luciferase units (RLU).
Stimulation of FLS with inflammatory cytokines
Inflammatory cytokines, including tumor necrosis factor
(TNF)-α (R&D), IL-1β (R&D), and IL-17 (R&D) were
added alone or in combination to the supernatants of
DMEM for incubation with FLS. The final concentra-
tions of these cytokines and length of incubation period
varied for different research targets.
Inhibition of signal pathways
Cultured FLS were incubated with inhibitors of p38, JNK,
ERK, and NF-kB for 30 min before IL-1β were added. The
inhibitors were SB203508 (Sigma, USA), SP600125 (Calbio-
chem, Merck), U0126 (Calbiochem, Merck), and PTDC
(Sigma, USA), respectively. The final concentration of IL-
1β was 0.1 ng/ml. Supernatant was recovered 24 h later for
detection of IL-6 with an ELISA kit (Dakewe, China).
Western blot analysis
Cultured FLS were washed with PBS, and protein was
extracted with lysis buffer (50 mM HEPES pH 8.0,
150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM
MgCl2, 1.5 mM EDTA, 20 mM β-glycerophosphate,
50 mM NaF, 1 mM Na3VO4, 10 μg/ml aprotonin, 1 μM
pepstatin A, 1 mM phenylmethylsulphonyl fluoride).
The protein concentrations were determined with the
DC protein assay kit (Bio-Rad, Hercules, CA, USA).
Whole cell lysates containing 50 μg of protein were
fractionated by 12% SDS-PAGE and transferred to a
nitrocellulose membrane. The membrane was blocked
with Tris-buffered saline plus 0.1% Tween 20 (TBST)
containing 5% non-fat milk for 1 h at room temperature
followed by incubation overnight with the appropriate
antibody at 4 °C. The membrane was washed three times
and incubated with horse radish peroxidase-conjugated
secondary antibody for 1 h. Immunoreactive protein was
detected by chemiluminescence with Kodak X-AR film
(Eastman Kodak, Rochester, NY, USA).ELISA
ELISA kits were used to detect rat IL-6 (R&D, USA) and
human IL-6 (Dakewe, China) or MMP-1 (R&D, USA) in
recovered supernatants. Procedures were carried out
following the instructions enclosed in the kits.CBA kit to detect inflammatory cytokines
Human FLS with different p53 status were cultured and
incubated with IL-1β or TNFα. After 24 h the supernatant
was harvested, and IL-17, TNFα, IL-2, IL-4, IL-10, and
IFN-γ were detected using a CBA kit (BD Bioscience).Cell proliferation assay
Alamar Blue assays incorporate a fluorimetric/colorimet-
ric growth indicator based on the detection of metabolic
activity. FLS (3 × 103) were plated into a 96-well plate
after siRNA transfection. At various time points,
medium was replaced by DMEM without phenol red
supplemented with 10% Alamar Blue. After incubation
for 4 h at 37 °C, fluorescence was measured with a
microplate reader at an excitation wavelength of 530 nm
and an emission wavelength of 590 nm. The number of
cells was expressed as relative fluorescence units.Statistical analysis
Data are expressed as means ± SEM. Statistics were per-
formed with Student’s t test, one-way analysis of vari-
ance and repeated-measures analysis of variance. A
comparison was considered significant at p < 0.05.Results
P53 reduced arthritis and synovitis in the AIA rats
To test the efficacy of p53 in treating inflammatory arth-
ritis, AIA in the Lewis rat model was used. Intraperitoneal
injection of Nutlin-3, a p53 activator, ameliorated arthritis
dramatically, including a significant decrease in arthritis
scores and joint swelling relative to the vehicle-treated
group (p < 0.05; Fig. 1a and b). There was a trend for in-
creased body weight in the Nutlin group compared to that
in the vehicle group (Fig. 1b). Histopathologic analysis indi-
cated that the synovium in Nutlin-treated rats was less in-
flamed than those treated with vehicle or PBS (Fig. 1e).
High levels of local IL-6 were measured in the serum
and joint homogenates using ELISA (Fig. 1c and d).
Nutlin significantly reduced IL-6 production in the
serum relative to the DMSO and PBS groups (p < 0.05).
Although there was no significant difference in joint
IL-6 levels between the Nutlin and vehicle groups or the
Nutlin and PBS groups (p > 0.05), a tendency for
decreased IL-6 with Nutlin was observed.
Fig. 1 Nutlin-3 attenuated arthritis and decreased IL-6 production in Lewis AIA rats. Lewis rats were immunized with complete Freund’s adjuvant,
and received Nutlin-3, dimethyl sulfoxide (DMSO), or phosphate-buffered saline (PBS) from day 8 to day 12 after immunization. Arthritis scores
were assessed every 3 days. a The mean arthritis scores. Nutlin significantly decreased arthritis, compared to DMSO (p = 0.16 and 0.02, respectively,
on day (d)13 and day 21). b Severity of inflammation was calculated by subtracting the volume of hind paw swelling between day 21 and day 8
after immunization (p = 0.04, Nutlin versus DMSO) and the body weight of the Nutlin group has a tendency to increase (p = 0.14, Nutlin versus
DMSO). c Interleukin-6 (IL-6) levels in the serum of the Nutlin group were significantly decreased compared to those in the DMSO and PBS groups
(p = 0.01 and 0.04, respectively). d IL-6 level in the joint (p = 0.09, Nutlin versus DMSO; p = 0.19, Nutlin versus PBS). e Nutlin-3 decreased infiltration
of inflammatory cells into the synovial tissue and bone erosion in AIA rats. Infiltration of inflammatory cells into the synovial tissue and pannus
formation were observed in DMSO and PBS group, but not in the Nutlin group. *p < 0.01
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apoptosis, in FLS
To address the mechanism of p53 on the therapy of in-
flammatory arthritis, we first delivered p53 to FLS using
adenovirus in vitro to identify the possible effects of p53
as a tumor suppressor, including regulation of the cell
cycle and induction of apoptosis. As previously noted,
ectopic expression of p53 did not induce apoptosis in
FLS. There were no significant differences between the
Ad-p53 treated group and the Ad-LacZ treated group
when counting dead cells with trypan blue staining
(Fig. 2a) or when measuring cell viability with the MTT
assay (Fig. 2b). Cell cycle analysis by flow cytometry in-
dicated that the p53-overexpressed FLS arrested at phase
G1 following transfection with Ad-p53 on days 3, 5, and
7, respectively (Fig. 2c). TUNEL staining demonstrated
less DNA fragmentation in Ad-p53 transfected FLS
in vitro (Fig. 2d, left panel) and in synovium from the
Ad-p53 treatment group in vivo (Fig. 2d, right panel).
Conversely, p53 knockdown significantly promoted
cell growth as measured by Alamar blue staining on day
4 and day 6 following the p53-siRNA transfection in FLS
(Fig. 2e). As expected, p21, a downstream protein of
p53, was also reduced following the suppression of p53
in FLS (Fig. 2f ). However, another classical downstream
factor of p53, Bax, was not changed following the alter-
ation of p53 status in FLS both at translational and
transcriptional levels detected by Western blot (Fig. 2g)and luciferase assay (Fig. 2h), consistent with the find-
ing that cell survival was not affected by ectopic
expression of p53.
Proinflammatory cytokines inhibited p53 expression in FLS
Based on the above results, we then investigated the role
of p53 in the process of inflammation in RA. To mimic
the inflammatory environment in the arthritis joint,
TNF-α, IL-1β, and IL-17 were used to treat FLS. p53
expression was decreased after 24 h of stimulation at a
dose-dependent manner in both the TNF-α and IL-1β
groups. IL-1β at 0.1 ng/ml dramatically reduced expres-
sion of p53, even to a greater extent than TNF-α at 10 ng/
ml (Fig. 3a). Then FLS were incubated with different
combinations of IL-1β at 0.01 or 0.1 ng/ml and IL-17 at
1 ng/ml or 10 ng/ml. IL-17 alone or in combination with
IL-1β also inhibited p53 expression in a dose-dependent
manner (Fig. 3b). Decreased expression of p21, a down-
stream protein of p53, further confirmed the inhibition of
p53, but Bax was not affected, which was also consistent
with our previous results with p53 (Fig. 2g).
p53 significantly suppressed the production of IL-6 in FLS
We then used p53 siRNA to reduce p53 expression by as
much as 98% in FLS (Fig. 2f). On the third day, p53-
deficient FLS were incubated with TNF-α or IL-1β for
24 h. IL-6 and MMP-1 concentrations in the supernatant
were measured by ELISA. Both TNF-α and IL-1β
Fig. 2 p53 did not induce apoptosis in FLS or the synovium (a–d), but did have control over cell growth (e–h). a Trypan blue staining 3 days
following transfection with Ad-LacZ and Ad-p53 at different multiplicity of infection (MOI). b MTT assay 3 days following transfection with Ad-LacZ
and Ad-p53 at different MOI. c Cell cycle in FLS following transfection with Ad-p53 (MOI = 100) on day (d)3, d5, and d7. d TUNEL staining on slides of
collected FLS (left) and synovium 3 days following Ad-p53 treatment (right). e Deletion of p53 in FLS increased cell growth as measured by Alamar blue
staining. *,p<0.05 f Deletion of p53 in FLS contribute to the lower expression of p21 thereafter. g Bax expression following knockdown of p53 was
analyzed by Western blot. h Effects of p53 expression on bax promotor activity in FLS as measured by luciferase assay. non, blank control. mock, mock
transfection. sc, scrambled RNA control
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ner, and p53 deficiency significantly amplified the increase
in IL-6 secretion following either TNF-α or IL-1β stimula-
tion (p ≤ 0.001). The amount of IL-6 production by FLS at
a TNF-α concentration of 10 ng/ml was similar to that ofFig. 3 Inflammatory cytokines inhibited expression of p53 in FLS in a dose
stimulation with TNF-α and IL-1β at 0.1, 1.0, and 10 ng/ml, respectively. b I
proteins p21 and p27, but not Bax. IL interleukin, TNF tumor necrosis factorIL-1β at 0.1 ng/ml, indicating that IL-1β had a stronger ef-
fect on stimulating IL-6 secretion than TNF-α (Fig. 4a and
b), but the production of other proinflammatory cytokines
by FLS following TNF-α or IL-1β stimulation in different
p53 statuses were undetectable, including IL-17, TNFα,-dependent manner. a p53 expression was reduced in FLS after the
L-1β and IL-17 synergistically inhibited expression of p53 and its related
Fig. 4 p53 modulated the production of proinflammatory factors in FLS. a Expression of IL-6 in FLS was efficiently inhibited following initial transfection of
p53 siRNA. After incubation with TNF-α for 24 h, IL-6 greatly increased in the p53-deleted FLS. b, c Inhibition of p53 resulted in more production of IL-6 as
well as MMP-1 after 24 h of incubation with IL-1β. d p53 suppressed the production of IL-6 in FLS following the stimulation of IL-1β. Ad adenovirus, IL
interleukin, MMP matrix metalloproteinase, sc scrambled RNA control, TNF tumor necrosis factor
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0.1 ng/ml and 1 ng/ml also significantly increased MMP-1
production in p53 siRNA-transfected FLS, compared with
scrambled siRNA-transfected FLS (p < 0.05; Fig. 4c).
To confirm the above results, we also treated the
Ad-p53 transfected FLS with IL-1β and found that over-
expression of p53 significantly inhibited IL-6 production
(p < 0.001; Fig. 4d).
p53 inhibited the activation of phosphorylated proteins in
different signal pathways to suppress inflammation in FLS
To address the mechanism of p53 controlling IL-6 pro-
duction in the synovium, the upstream signal transduc-
tion pathways in the inflammatory process of RA were
investigated. FLS with varying p53 status were prepared,
including p53 knockdown, wild-type (wt) p53, and p53
overexpressed. Cells were then stimulated with IL-1β for15 min and evaluated by Western blot analysis for NF-
κB and MAPK pathways (Fig. 5a and b). p53 deficiency
significantly augmented phosphorylation of IkBα, p38,
JNK, and ERK in the FLS, while overexpression of p53
significantly reduced phosphorylation of the same pro-
teins. The results strongly indicated that p53 inhibited
inflammation-related signal transduction in FLS.
To confirm the above results, indicating the role of
p53 in different signal pathways, we treated FLS with
SB203580 for the inhibition of p38, SP600125 for JNK,
U0126 for ERK, and PTDC for NF-κB, respectively, 1 h
earlier than incubating with IL-1β (0.1 ng/ml), and then
measured the IL-6 levels in the supernatants. In p53-
deleted FLS, production of IL-6 was significantly blocked
by the signal transduction inhibitors (Fig. 5c). The effect
of each of the inhibitors on the suppression of IL-6 in
p53-deficient FLS was similar to that of overexpression
Fig. 5 p53 in FLS strongly controls different signal pathways to suppress proinflammatory cytokine production. a, b Different p53 status in FLS,
including deficient p53, wild-type p53, and overexpressed p53, regulated the phosphorylation of p38, JNK, and ERK, as well as IkBα in the FLS.
c p53 insufficiency in FLS promoted the inflammatory cytokine production, which was significantly blocked by different signal transduction
inhibitors, similar to the effects of overexpressed p53 on the suppression of IL-6 production in FLS (Fig. 4d; Ad-p53 + IL-1β). Ad adenovirus, IL
interleukin, TNF tumor necrosis factor
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FLS (Fig. 4d). The results might suggest that the intrinsic
mechanism of p53 inhibiting inflammation is via pro-
foundly suppressing signal transduction pathways.
Discussion
RA is a chronic inflammatory disease with synovitis as
its primary pathologic change. Nutlin-3A (a p53 activa-
tor), showing promising efficacy in the therapy of the
AIA model through activation of p53, inhibits arthritic
synovitis in vivo. In RA-FLS, expression of p53 was
suppressed by cytokines, including IL-1β, TNF-α and
IL-17, leading to subsequent stimulation of IL-6 produc-
tion by activating the NF-κB and MAPK pathways.
NF-κB is one central component involved in all
inflammation-associated conditions and all stages of in-
flammation. In our experiment, the suppression of p53
by inflammatory cytokines resulted in NF-κB activation.
This phenomenon was consistently found in cancer. The
majority of tumors with constitutive expression of NF-
κB are p53 deficient. Other studies have revealed that
NF-κB upregulates the levels of the major p53 inhibitor(Mdm2) [13–15], phosphorylates p53 through IKKβ
[16], and induces anti-apoptotic factors to neutralize the
pro-apoptotic effects of p53 [17]. Therefore, activation
of NF-κB shutting down p53 function and responses in
some cancer cells may also apply to chronic inflamma-
tion in RA synovium, leading to long-lasting p53 defi-
ciency with mutant p53.
p53 also appears to act as a repressor of NF-κB in vivo
since several reports using p53-null mice and wild-type
mice demonstrated that p53 reduced inflammation in
animal models, including CIA [9], experimental auto-
immune encephalitis [18], and inflammatory lung injury
caused by bleomycin [19, 20]. p53, responding to intrin-
sic stresses, limits the consequences of stress by initiat-
ing cell death, senescence, or cell cycle arrest, and
promotes metabolic patterns in the cell to favor oxida-
tive phosphorylation, while NF-κB promotes cell div-
ision. On activation of one of these transcription factors,
the other is inactivated [21]. Some research groups
suggest that their reciprocal inhibition is due to the
common use of a limiting pool of co-activators [22–24].
Others reported a p53-mediated increase in IκB
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sequesters NF-κB signaling in the cytoplasm [25–27]. In
addition, a direct association between p53 and p65,
which mutually compromises their activation potential,
has also been reported [28].
Besides NF-κB, the phosphorylation of all three main
kinases in the MAPK pathway is also upregulated by p53
deficiency in FLS, including the stress-activated protein
kinase (SAPK/c-Jun N-terminal protein kinase (JNK)),
the p38 mitogen-activated protein kinase (p38), and the
extracellular signal-related kinase (ERK). Recent reports
of MAPK inhibitory phosphorylases as p53 targets have
provided a more complex and comprehensive picture of
how p53 functionally interacts with the MAPK signaling
pathway. Activation of phosphatases by p53 negatively
regulates MAPK-dependent signaling, including Wip1,
MKP1, PAC, and DUSP5 [29–32]. These four phospha-
tases are capable of inactivating the MAPK signaling
pathways through dephosphorylation [33]. Our research
on the relationship between p53 and MAPK as well as
NF-κB signaling pathways in synovial fibroblasts were
consistent with those former results from cancer cells.
IL-6 is a key cytokine involved in the pathogenesis of
RA, and recent research has demonstrated its central role
in regulating the balance between IL-17 producing T
helper (TH17) cells and regulatory T (Treg) cells. TH17
cells are potent inducers of IL-6, IL-8, MMP-1, and
MMP-3 expression by the FLS [34], acting as the primary
proinflammatory effector cells involved in RA [35]. Treg
cells have an anti-inflammatory role and maintain toler-
ance to self-components [36], restraining excessive ef-
fector T-cell responses [35]. In the peripheral blood of
patients with active RA, levels of TH17 cells are increased
while Treg cells decreased [37]. IL-6 has been recognized
as a regulator of the TH17/Treg balance. IL-6 induces the
development of TH17 cells from naïve T cells together
with transforming growth factor (TGF)-β, while inhibiting
TGF-β promotes Treg differentiation [35]. In RA syno-
vium, synovial fibroblast-derived IL-6 has a crucial role in
the conversion of Foxp3 + CD4+ cells to TH17 cells.
These TH17 cells are more potent osteoclastogenic T cells
than naive CD4+ T cell-derived TH17 cells [38]. Treat-
ment with the anti-IL-6 receptor antibody tocilizumab in-
duces a significant decrease in the percentage of TH17
cells and an increase in the percentage of Treg cells in RA
patients, resulting in a correction of the TH17/Treg cell
imbalance [37, 39]. Although controversial results suggest
unaffected TH17 cells with upregulated Treg cells after
anti-IL-6 receptor treatment, there is a trend that TH17
cells are decreased [40–42]. So, combined with our
results, we assume that p53 deficiency in RA promotes
arthritic inflammation through upregulation of IL-6,
which exerts its pivotal role by converting Tregs to TH17
cells. This has also been supported by the results fromNingli Li et al, demonstrating that Cyr61, an extracellular
matrix protein regulated by p53, promotes IL-6 secretion
as well as subsequent TH17 differentiation [43–45].
Thus, we hypothesize that p53 plays a key role in inhibit-
ing synovial inflammation; the inflammation of the syno-
vium in RA significantly inhibits p53 expression or leads to
p53 mutation and dysfunction. In turn, suppressed p53 in
synovial fibroblasts facilitates the activation of NF-κB and
MAPK pathways, resulting in increased secretion of IL-6
which further inhibits p53 probably throughTH17/Treg dis-
turbance. This vicious feedback loop contributes to the per-
petuation of inflammation and joint destruction in RA.
Besides involvement in synovial inflammation, our study
also revealed that p53 controlled cell growth but failed to
induce apoptosis in FLS. Increased cell growth following
knockout of p53 in FLS is well explained by decreased ex-
pression of p21 and promoted phosphorylation of ERK.
ERK is known to regulate cellular proliferation and differ-
entiation [46], and p21 is tightly controlled by p53,
through which p21 mediates the p53-dependent cell cycle
arrest in response to a variety of stress stimuli [47]. Inhib-
ition of p53 in FLS leads to reduced p21, which then af-
fects both cell cycles and inflammation [48].
We also measured Bax, the Bcl-2-associated X protein,
which is well recognized in p53-mediated apoptosis such as
PUMA (p53-upregulated modulator of apoptosis) [49, 50].
However, in RA-FLS, PUMA-induced apoptosis does not
require p53 [51]. Expression and function of Bax also does
not change when p53 is deleted. This result is different from
a previous report in which mutant p53 reduced Bax level in
dermal fibroblasts [7]. In that paper, chemical transfection
with mutant p53 was used rather than the siRNA technique.
Although Bax is a key pro-apoptotic effector of p53 in most
of the cases, it is possible that p53 does not control Bax in
the specific tissue of synovium, and it gives us a reasonable
explanation why p53 cannot induce apoptosis in FLS,
suggesting that there might be other mechanisms for
aberrant apoptosis induced by p53 in RA synovium.
Besides being deficient in FLS, p53 is also recognized
to be reduced in peripheral blood mononuclear cells
from patients with RA. The study by Maas et al. suggests
that defects in the expression of p53 mRNA in the lym-
phocytes leads to severe defects in apoptosis in patients
with RA [52]. Combined with our research, further in-
vestigation is needed to determine the precise effects,
other than apoptosis, of p53 in lymphocytes.
Conclusions
In addition to its regulation of the cell cycle and
apoptosis, p53 might play a crucial role in suppressing
synovial inflammation by interaction with signal trans-
duction pathways and regulating the production of in-
flammatory mediators to control RA (Fig. 6). Therefore,
p53 may be a key player in the complicated network of
Fig. 6 p53 plays a pivotal role in inhibiting synovial inflammation. The inflammation of the synovium in RA significantly inhibits p53 expression or
leads to p53 dysfunction. In turn, suppressed p53 results in increased secretion of IL-6, which further suppresses p53, probably by modulating
Th17 differentiation. FLS fibroblast-like synoviocytes, IL interleukin, TNF tumor necrosis factor, TH17 IL-17 producing T helper, Treg regulatory T
Zhang et al. Arthritis Research & Therapy  (2016) 18:271 Page 9 of 10synovial inflammation, proliferation, and apoptosis, mak-
ing it a potential target for gene and biologic therapeutic
strategies in RA.
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